Fondaparinux is used to prevent and treat deep vein thrombosis (DVT) and pulmonary embolism (PE) by selectively inhibiting Factor Xa. It is used as a safer alternative to heparin for patients with a history of Heparin-Induced Thrombocytopenia (HIT).

It is used for the prevention of deep vein thrombosis in patients who have had orthopedic surgery as well as for the treatment of deep vein thrombosis and pulmonary embolism. It can csubstantially reduce major bleeding and improves long-term mortality and morbidity. It has been investigated for use in conjunction with streptokinase.

One advantage of fondaparinux over LMWH or unfractionated heparin is that the risk for heparin-induced thrombocytopenia (HIT) is substantially lower. Furthermore, there have been case reports of fondaparinux being used to anti-coagulate patients with established HIT.

It’s appearance is white powder solid, soluble in water, the Purity (HPLC) is more than 99.5%. the quality complies with USP40, and the batch capacity is 5–6 kg/ batch.